Annovis Bio downgraded by D. Boral Capital
$ANVS
Biotechnology: Pharmaceutical Preparations
Health Care
D. Boral Capital downgraded Annovis Bio from Buy to Hold
Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 2/10/2025 | Buy → Hold | D. Boral Capital | |
| 10/25/2024 | $25.00 | Hold → Buy | Maxim Group |
| 12/29/2023 | $36.00 | Buy | Canaccord Genuity |
| 7/7/2021 | $45.00 → $150.00 | Buy | Maxim Group |
MALVERN, Pa., June 26, 2025 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE:ANVS) ("Annovis" or the "Company"), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD), today announced its senior management will attend the Alzheimer's Association International Conference (AAIC), taking place July 27–31, 2025, in Toronto, Canada. The Company will present four scientific posters highlighting advances of Alzheimer's clinical program and pharmacokinetic characterization of its lead drug candidate, buntanetap. Presentation details: Poster #1: Design of Phase III study testi
MALVERN, Pa., June 19, 2025 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE:ANVS) ("Annovis" or the "Company"), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD), today announced it received notification (the "Acceptance Letter") from the New York Stock Exchange ("NYSE") that the NYSE has accepted the Company's previously-submitted plan (the "Plan") to regain compliance with the NYSE's continued listing standards relating to minimum market capitalization and stockholders' equity. In the Acceptance Letter, the NYSE granted the Company an 18-month period from the Company's
MALVERN, Pa., June 05, 2025 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE:ANVS) ("Annovis" or the "Company"), a clinical-stage drug platform company developing novel therapies for neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD), today announced it will host a live webcast where Maria Maccecchini, Ph.D., President and CEO, will provide updates and answer questions from the audience. Webcast Details Date: June 24, 2025Time: 4:30 PM EDTRegistration: Click here to register During the webcast, Dr. Maccecchini will share progress on the ongoing pivotal Phase 3 trial in early AD, the FDA's feedback on the continued development of the PD program, and other
D. Boral Capital downgraded Annovis Bio from Buy to Hold
Maxim Group upgraded Annovis Bio from Hold to Buy and set a new price target of $25.00
Canaccord Genuity initiated coverage of Annovis Bio with a rating of Buy and set a new price target of $36.00
8-K - Annovis Bio, Inc. (0001477845) (Filer)
8-K - Annovis Bio, Inc. (0001477845) (Filer)
8-K - Annovis Bio, Inc. (0001477845) (Filer)
4 - Annovis Bio, Inc. (0001477845) (Issuer)
4 - Annovis Bio, Inc. (0001477845) (Issuer)
4 - Annovis Bio, Inc. (0001477845) (Issuer)
MALVERN, Pa., April 29, 2025 (GLOBE NEWSWIRE) -- Annovis Bio Inc. (NYSE:ANVS) ("Annovis" or the "Company"), a late-stage clinical drug platform company developing transformative therapies for neurodegenerative disorders such as Alzheimer's disease (AD) and Parkinson's disease (PD), today announced the appointment Hui Liu as Director of Biostatistics. "Bringing Ms. Liu on board at this critical stage, as our pivotal Phase 3 AD trial advances, reinforces our commitment to scientific excellence," said Cheng Fang, Ph.D., Senior Vice President, Research and Development. "Her statistical expertise will help ensure the integrity of our data and support robust regulatory submissions as we move to
MALVERN, Pa., Nov. 07, 2024 (GLOBE NEWSWIRE) -- via IBN -- Annovis Bio Inc. (NYSE:ANVS) ("Annovis" or the "Company"), a late-stage clinical drug platform company developing transformative therapies for neurodegenerative disorders such as Alzheimer's disease (AD) and Parkinson's disease (PD), today announced the appointment of Matthew Peterson, Ph.D., as Senior Clinical Scientist. Dr. Peterson will be responsible for medical, ethical, and scientific quality and rigor in the initiation, conduct, reporting, and successful completion of Annovis' clinical trials. "We are thrilled to welcome Matthew Peterson to our team," said Cheng Fang, Ph.D., Senior Vice President, Research and Development,
BERWYN, Pa., Dec. 01, 2023 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE:ANVS), a clinical-stage drug platform company developing novel therapies for neurodegenerative diseases such as Alzheimer's (AD) and Parkinson's disease (PD) today announced the appointment of Andrew Walsh as VP, Finance. "We remain steadfast in advancing our lead candidate buntanetap, as we gear up to receive pivotal data from both our Alzheimer's and Parkinson's clinical trials in 2024. The addition of Andrew Walsh to our team marks another step in our growth plans," said Maria Maccecchini, Ph.D., Founder, President, and CEO of Annovis. "Andrew brings 12 years of extensive experience in finance operations, adding a
Data Shows Statistically Significant Improvements in Speed and Motor Function in PD PatientsAnnovis Bio to Request Meeting with FDA on Next Steps in Clinical DevelopmentInvestor Conference Call to be Hosted Tuesday, October 5th, 2021, at 9:00 am ETBerwyn, Pennsylvania--(Newsfile Corp. - October 5, 2021) - Annovis Bio, Inc. (NYSE:ANVS) ("Annovis" or the "Company"), a clinical-stage drug platform company addressing Alzheimer's disease (AD), Parkinson's disease (PD) and other neurodegenerative diseases, today announced results from the completed dose response Phase 2 clinical trial of ANVS401 in 54 PD patients, which found that once-daily ANVS401 was superior to placebo in improving motor funct
SC 13G/A - Annovis Bio, Inc. (0001477845) (Subject)
SC 13G - Annovis Bio, Inc. (0001477845) (Subject)